» Articles » PMID: 33563823

Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19

Abstract

Whether mother-to-infant SARS-CoV-2 transmission can occur during breastfeeding and, if so, whether the benefits of breastfeeding outweigh this risk during maternal COVID-19 illness remain important questions. Using RT-qPCR, we did not detect SARS-CoV-2 RNA in any milk sample (= 37) collected from 18 women following COVID-19 diagnosis. Although we detected evidence of viral RNA on 8 out of 70 breast skin swabs, only one was considered a conclusive positive result. In contrast, 76% of the milk samples collected from women with COVID-19 contained SARS-CoV-2-specific IgA, and 80% had SARS-CoV-2-specific IgG. In addition, 62% of the milk samples were able to neutralize SARS-CoV-2 infectivity , whereas milk samples collected prior to the COVID-19 pandemic were unable to do so. Taken together, our data do not support mother-to-infant transmission of SARS-CoV-2 via milk. Importantly, milk produced by infected mothers is a beneficial source of anti-SARS-CoV-2 IgA and IgG and neutralizes SARS-CoV-2 activity. These results support recommendations to continue breastfeeding during mild-to-moderate maternal COVID-19 illness. Results from prior studies assaying human milk for the presence of SARS-CoV-2, the causative virus of COVID-19, have suggested milk may act as a potential vehicle for mother-to-child transmission. Most previous studies are limited because they followed only a few participants, were cross-sectional, and/or failed to report how milk was collected and/or analyzed. As such, considerable uncertainty remains regarding whether human milk is capable of transmitting SARS-CoV-2 from mother to child. Here, we report that repeated milk samples collected from 18 women following COVID-19 diagnosis did not contain SARS-CoV-2 RNA; however, risk of transmission via breast skin should be further evaluated. Importantly, we found that milk produced by infected mothers is a source of anti-SARS-CoV-2 IgA and IgG and neutralizes SARS-CoV-2 activity. These results support recommendations to continue breastfeeding during mild-to-moderate maternal COVID-19 illness as milk likely provides specific immunologic benefits to infants.

Citing Articles

Prenatal SARS-CoV-2 Infection Alters Human Milk-Derived Extracellular Vesicles.

Chutipongtanate S, Kongsomros S, Cetinkaya H, Zhang X, Kuhnell D, Benefield D Cells. 2025; 14(4).

PMID: 39996756 PMC: 11853888. DOI: 10.3390/cells14040284.


Healthcare providers' hospital breastfeeding practices during the COVID-19 endemic and associated factors in Thailand: a cross-sectional study.

Lawin N, Nuampa S, Somsuk C, Srisawad S, Raungrongmorakot K, Ketsuwan S BMC Nurs. 2024; 23(1):840.

PMID: 39551745 PMC: 11569598. DOI: 10.1186/s12912-024-02498-4.


Antibodies in breast milk: Pro-bodies designed for healthy newborn development.

Verhasselt V, Tellier J, Carsetti R, Tepekule B Immunol Rev. 2024; 328(1):192-204.

PMID: 39435770 PMC: 11659933. DOI: 10.1111/imr.13411.


Associations between SARS-CoV-2 Infection or COVID-19 Vaccination and Human Milk Composition: A Multi-Omics Approach.

Couvillion S, Nakayasu E, Webb-Robertson B, Yang I, Eder J, Nicora C J Nutr. 2024; 154(12):3566-3574.

PMID: 39396761 PMC: 11662230. DOI: 10.1016/j.tjnut.2024.09.032.


Factors Influencing Breast Milk Antibody Titers during the Coronavirus Disease 2019 Pandemic: An Observational Study.

Hochmayr C, Winkler I, Hammerl M, Holler A, Huber E, Urbanek M Nutrients. 2024; 16(14).

PMID: 39064762 PMC: 11280407. DOI: 10.3390/nu16142320.


References
1.
. Timing of initiation, patterns of breastfeeding, and infant survival: prospective analysis of pooled data from three randomised trials. Lancet Glob Health. 2016; 4(4):e266-75. DOI: 10.1016/S2214-109X(16)00040-1. View

2.
. Breastfeeding and the use of human milk. Pediatrics. 2012; 129(3):e827-41. DOI: 10.1542/peds.2011-3552. View

3.
Dong Y, Chi X, Hai H, Sun L, Zhang M, Xie W . Antibodies in the breast milk of a maternal woman with COVID-19. Emerg Microbes Infect. 2020; 9(1):1467-1469. PMC: 7475804. DOI: 10.1080/22221751.2020.1780952. View

4.
Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

5.
Liu Y, Yan L, Wan L, Xiang T, Le A, Liu J . Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020; 20(6):656-657. PMC: 7158902. DOI: 10.1016/S1473-3099(20)30232-2. View